|Friday, 17 May 2019, 15:34 HKT/SGT|
TOKYO, May 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction.
"SBT Initiative" is an international joint initiative by CDP which is an international NGO operating information disclosure program related to the environment field, the UN Global Compact (UNGC), the World Wildlife Fund (WWF), and the World Resources Institute (WRI). Paris Agreement includes to keep the global average temperature rise since pre-industrial revolution to below 2degC as a long-term common global goal for GHG reduction. According to this adaptation of Paris Agreement, SBT Initiative certifies companies with ambitious targets meeting the SBT "2degC target". "SBT Initiative" certified that the following Eisai's GHG emission reduction targets are recognized as based on scientific grounds and therefore approved.
- 30% reduction of GHG emission (Scope 1 and 2) by FY2030 from FY2016
- 30% reduction of GHG emission (emission based on purchased products and services in Scope 3) by FY2030 from FY2016
Scope 1: Direct emission of GHG released into the air by the use of fossil fuel
Scope 2: Indirect emission of GHG with use of electricity and steam purchased from others
Scope 3: Indirect emission of GHG by supply chain excluding Eisai
Eisai's corporate philosophy is to give first thought to patients and their families, and increase that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will strengthen the activities for climate changes and contributes to ensure the society sustainability.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com
Public Relations Department,
Eisai Co., Ltd.
May 17, 2019 15:34 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.